drugset / Trial / NCT04699968
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
Timeline
- Start
- 2021-01-15
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | — | Oral |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |